2025-10-04 - Analysis Report
Okay, here's a comprehensive analysis of Johnson & Johnson (JNJ) based on the provided information, presented in English with key numerical data and analysis.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** JNJ
*   **Company Overview:** Johnson & Johnson is a global healthcare company focused on pharmaceuticals, medical devices, and consumer health products.
*   **JNJ Cumulative Return:** 45.27%
*   **VOO Cumulative Return:** 98.51%
*   **Absolute Deviation:** -53.24% (JNJ underperformed VOO by this amount)
*   **Deviation Range (Max/Min/Current):** 16.6 / -65.5 / -55.3
*   **Relative Deviation:** 12.4 (Indicates JNJ's current underperformance is closer to its historical minimum than its maximum relative to VOO.)

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD    | Alpha  | Beta  | Cap(B) |
| ---------- | ------ | ------ | ------ | ----- | ------ |
| 2015-2017  | 26.0%  | 66.8%  | -2.0%  | -0.1  | 336.5  |
| 2016-2018  | 14.0%  | 10.7%  | -1.0%  | 0.1   | 310.8  |
| 2017-2019  | 20.0%  | 71.5%  | -2.0%  | 0.4   | 351.3  |
| 2018-2020  | 19.0%  | 79.2%  | -4.0%  | 0.4   | 379.0  |
| 2019-2021  | 33.0%  | 79.2%  | -14.0% | 0.5   | 412.0  |
| 2020-2022  | 8.0%  | 79.6%  | 9.0%   | 0.4   | 425.4  |
| 2021-2023  | -19.0% | 79.6%  | -20.0% | 0.3   | 377.5  |
| 2022-2024  | -32.0% | 79.6%  | -53.0% | 0.3   | 348.3  |
| 2023-2025  | 16.0%  | 79.6%  | -47.0% | 0.1   | 454.3  |

*   **Analysis:** JNJ has significantly underperformed the S&P 500. The negative Alpha values across most periods suggest JNJ has not generated excess returns compared to the benchmark.  Beta values are generally low, indicating lower volatility than the market. High MDD (Maximum Drawdown) values suggest significant potential for loss during downturns.

**2. Recent Price Action**

*   **Current Price:** \$188.64
*   **Previous Close:** \$185.98
*   **Change:** \$1.43
*   **5-day Moving Average:** \$185.75
*   **20-day Moving Average:** \$179.12
*   **60-day Moving Average:** \$173.88

*   **Analysis:** JNJ is trading above all three moving averages, suggesting an upward trend.  The recent positive change (\$1.43) indicates short-term bullish momentum. The price is up a fair amount from the last close.

**3. Market Risk Indicator and other Indexes**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 74.12 (Overbought territory, suggesting potential for a pullback)
*   **PPO:** 0.56 (Positive, indicating an upward trend)
*   **Hybrid Signal:** Cash_0%_Buy 100% of cash (5 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment (\$1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Recent (20-day) Relative Deviation Change:** 0.3 (+) (Short-term upward momentum in relative performance)
*   **Expected Return:** -144.3% (Significant underperformance vs. S&P 500 expected over a long-term investment horizon.)

*   **Analysis:** The high MRI suggests a favorable overall market environment for investment. However, the RSI indicates JNJ may be overbought in the short term. The significantly negative Expected Return is a major concern, indicating potential for substantial underperformance compared to the S&P 500 over the long term.

**4. Recent News & Significant Events**

*   **[2025-10-03] Johnson & Johnson (JNJ) Rises Higher Than Market: Key Facts (Zacks)**
*   **[2025-10-03] Stocks to Watch Recap: Apple, Applied Materials, Chevron, Broadcom (The Wall Street Journal)**
*   **[2025-10-03] How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment (Investor's Business Daily)**
*   **[2025-10-03] Sector Update: Health Care Stocks Gain Late Afternoon (MT Newswires)**
*   **[2025-10-03] Johnson & Johnson Stock Climbs As Wells Fargo Boosts Rating And Price Target (GuruFocus.com)**
*   **[2025-10-03] Johnson & Johnson Shares Rise After Upgrade From Wells Fargo (MT Newswires)**

*   **Analysis:** Recent news is generally positive, with articles highlighting JNJ's recent gains, an upgrade from Wells Fargo, and a positive sector update for healthcare stocks. This positive sentiment may be contributing to the recent price increase.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (~2.12 on a 1-5 scale)
*   **Opinions:** 23 analysts
*   **Target Price (Avg/High/Low):** \$183.42 / \$212.00 / \$155.00
*   **Recent Rating Changes:**  (No specific changes provided, but the overall consensus is "Buy").

*   **Analysis:**  The analyst consensus is "Buy," but the average target price is below the current price (\$188.64), suggesting limited upside potential according to analysts.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue      |
| ---------- | ---- | ------------ |
| 2025-07-24 | 2.3  | \$23.74 B    |
| 2025-04-23 | 4.57 | \$21.89 B    |
| 2024-10-23 | 1.12 | \$22.47 B    |
| 2024-07-25 | 1.95 | \$22.45 B    |
| 2025-07-24 | 1.95 | \$22.45 B$    |

*   **Analysis:** Revenue has been relatively stable. EPS shows some variation.

**6. Financial Information**

**Revenue and Profitability**

| Quarter    | Revenue   | Profit Margin |
| ---------- | --------- | ------------- |
| 2025-06-30 | \$23.74B  | 67.87%        |
| 2025-03-31 | \$21.89B  | 66.40%        |
| 2024-12-31 | \$22.52B  | 68.35%        |
| 2024-09-30 | \$22.47B  | 69.01%        |
| 2024-06-30 | \$22.45B  | 69.40%        |

**Capital and Profitability**

| Quarter    | Equity    | ROE     |
| ---------- | --------- | ------- |
| 2025-06-30 | \$78.47B  | 7.06%   |
| 2025-03-31 | \$78.11B  | 14.08%  |
| 2024-12-31 | \$71.49B  | 4.80%   |
| 2024-09-30 | \$70.16B  | 3.84%   |
| 2024-06-30 | \$71.54B  | 6.55%   |

*   **Analysis:**  Revenue is consistent. Profit margins are strong and relatively stable. Equity has generally increased. ROE fluctuates, indicating variations in profitability relative to shareholder equity.

**7. Overall Analysis & Summary**

*   **JNJ has significantly underperformed the S&P 500 over the period.** The negative Alpha and substantial negative Expected Return are concerning.
*   **Recent price action is positive,** with JNJ trading above its moving averages.
*   **The RSI indicates the stock may be overbought in the short term.**
*   **Analyst consensus is "Buy,"** but the average target price is below the current price, indicating limited near-term upside.
*   **Financial performance (revenue, profit margins) is solid.**
*   **Recent news is positive,** potentially driving the recent price increase.
*   **Key Risks:** The significant underperformance compared to the S&P 500 and the negative Expected Return are the most significant risks. The high MDD also suggests potential for large losses during market downturns.
*   **Overall, while JNJ shows some positive short-term signals, the long-term underperformance and negative expected return warrant caution.**

